Molecular Partners AG (OTCMKTS:MLLCF – Get Rating) was the target of a significant decrease in short interest during the month of December. As of December 15th, there was short interest totalling 113,400 shares, a decrease of 30.0% from the November 30th total of 162,100 shares. Based on an average daily volume of 500 shares, the days-to-cover ratio is presently 226.8 days.
Molecular Partners Stock Up 5.8 %
OTCMKTS MLLCF opened at $6.17 on Monday. Molecular Partners has a 52 week low of $5.16 and a 52 week high of $32.00. The firm's 50-day simple moving average is $6.39 and its two-hundred day simple moving average is $6.19.
Get
Molecular Partners alerts:
Molecular Partners Company Profile
(Get Rating)
Molecular Partners AG operates as a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic proteins. Its products candidates include Abicipar, a DARPin therapeutic candidate, which is in Phase III clinical trials for the treatment of neovascular wet age-related macular degeneration, as well as for diabetic macular edema; and MP0420, a multi-specific DARPin therapeutic candidate for the SARS-CoV-2 virus.
See Also
- Get a free copy of the StockNews.com research report on Molecular Partners (MLLCF)
- MarketBeat: Week in Review 12/26 – 12/30
- The Dogs Of Tech: It's Time For A Bite Of These Stocks
- Does This Acquisition Make Microsoft a Bear Market Buy?
- Should You Warm up to Generac Stock for the Winter?
- Is Kintara Therapeutics A Hidden Gem?
Receive News & Ratings for Molecular Partners Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Molecular Partners and related companies with MarketBeat.com's FREE daily email newsletter.
分子伙伴股份公司(场外交易市场代码:MLLCF-GET Rating)是空头股数12月份大幅下降的目标。截至12月15日,空头股数共有11.34万股,比11月30日的16.21万股减少了30.0%。以日均成交量500股计算,目前天数与回补比率为226.8天。
分子合作伙伴股票上涨5.8%
OTCMKTS MLLCF周一开盘报6.17美元。Molecal Partners的52周低点为5.16美元,52周高位为32.00美元。该公司的50日简单移动均线切入位为6.39美元,200日简单移动均线切入位为6.19美元。
到达
分子伴侣警报:
分子合作伙伴公司简介
(获取评级)
分子伙伴公司是一家临床阶段的生物制药公司,专注于治疗性蛋白质的发现、开发和商业化。它的候选产品包括用于治疗新血管湿性老年性黄斑变性和糖尿病黄斑水肿的候选DARPin药物Abempar,该药物处于第三阶段临床试验;以及针对SARS-CoV-2病毒的多特异性DARPin候选药物MP0420。
另请参阅
- 免费获取StockNews.com关于分子伙伴的研究报告(MLLCF)
- MarketBeat:回顾一周12/26-12/30
- 科技狗:是时候咬一口这些股票了
- 这笔收购会让微软成为熊市买入者吗?
- 你应该热身到Generac股票过冬吗?
- 金塔拉治疗公司是一颗隐藏的宝石吗?
每日收到分子合作伙伴的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯,接收分子合作伙伴和相关公司的最新新闻和分析师评级的每日摘要。